Novo Nordisk A/SNVONYSE
Loading
Asset Growth Under PressureDecelerating
Percentile Rank56
3Y CAGR-79.1%
5Y CAGR-5.8%
Year-over-Year Change
Year-over-year total asset growth rate
3Y CAGR
-79.1%/yr
vs +325.0%/yr prior
5Y CAGR
-5.8%/yr
Recent deceleration
Acceleration
-404.1pp
Decelerating
Percentile
P56
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 5.98% |
| Q3 2025 | 6.25% |
| Q2 2025 | -1.43% |
| Q1 2025 | 5.02% |
| Q4 2024 | 17.20% |
| Q3 2024 | 648.67% |
| Q2 2024 | -82.24% |
| Q1 2024 | -4.95% |
| Q4 2023 | 638.08% |
| Q3 2023 | 3.58% |
| Q2 2023 | 12.81% |
| Q1 2023 | -84.89% |
| Q4 2022 | 654.05% |
| Q3 2022 | 3.96% |
| Q2 2022 | 4.37% |
| Q1 2022 | -84.84% |
| Q4 2021 | 616.89% |
| Q3 2021 | 7.62% |
| Q2 2021 | 12.84% |
| Q1 2021 | -6.21% |
| Q4 2020 | 8.05% |
| Q3 2020 | 7.48% |
| Q2 2020 | 10.49% |
| Q1 2020 | -1.61% |
| Q4 2019 | -84.89% |
| Q3 2019 | 5.94% |
| Q2 2019 | 7.06% |
| Q1 2019 | -0.57% |
| Q4 2018 | 8.71% |
| Q3 2018 | -1.31% |
| Q2 2018 | 10.36% |
| Q1 2018 | -8.59% |
| Q4 2017 | 4.56% |
| Q3 2017 | 0.07% |
| Q2 2017 | 3.83% |
| Q1 2017 | -3.41% |
| Q4 2016 | 11.68% |
| Q3 2016 | -1.05% |
| Q2 2016 | 7.16% |
| Q1 2016 | -10.27% |